Global study to evaluate the reduction of levodopa-induced dyskinesia (PD LID)
Milan, Italy – March 15, 2021 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5),
Final study data intended to support the initiation of Newron’s planned phase III pivotal trial program for evenamide
Milan, Italy and Morristown, NJ, USA, January 21, 2021 -
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
